Ascendiant Capital Markets initiated coverage on Alzamend Neuro with a new price target

10/1/21 7:11:54 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Ascendiant Capital Markets initiated coverage of Alzamend Neuro with a rating of Buy and set a new price target of $8.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALZN

Date	Price Target	Rating	Analyst
10/1/2021	$8.00	Buy	Ascendiant Capital Markets